Acetazolamide Per os for Decompensation of Heart Failure
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery
disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be
noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF),
while its prevalence is progressively increasing annually.
Acute decompensation of CHF is understood as a rapid increase in the severity of clinical
manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial
hypotension), which caused urgent medical treatment and emergency hospitalization in a
patient already suffering from CHF. Decompensation of CHF requires intensification of
treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in
addition to standard therapy helps to reduce edematous syndrome.